A phase I study to evaluate safety, pharmacokinetics, and pharmacodynamics of respiratory syncytial virus neutralizing monoclonal antibody MK‐1654 in healthy Japanese adults

• Published in: Clinical and Translational Science Vol. 15; no. 7; pp. 1753 - 1763
• Main Authors: Orito, Yuji, Otani, Naoyuki, Matsumoto, Yuki, Fujimoto, Katsukuni, Oshima, Nobuyuki, Maas, Brian M., Caro, Luzelena, Aliprantis, Antonios O., Cox, Kara S., Tokumaru, Osamu, Kodama, Masaaki, Kudo, Hideo, Imai, Hiromitsu, Uemura, Naoto
• Format: Journal Article
• Language: English
• Published: United States Wiley 01.07.2022; John Wiley & Sons, Inc; John Wiley and Sons Inc
• Subjects: Adult; Age; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Babies; Bioavailability; Disease; Diseases; Dosage; Drug dosages; Drug therapy; Hospital costs; Hospitalization; Humans; Infant; Infants; Infections; Intravenous administration; Japan; Laboratories; Monoclonal antibodies; Morbidity; Mortality; Palivizumab; Pharmacodynamics; Pharmacokinetics; Placebos; Population; Proteins; Public aspects of medicine; RA1-1270; Respiratory syncytial virus; Respiratory Syncytial Virus Infections; Respiratory Syncytial Virus, Human; Respiratory tract diseases; RM1-950; Seasons; Surveillance; Therapeutics. Pharmacology; Vaccines; Viral infections; Vital signs; Japan
• ISSN: 1752-8054; 1752-8062; 1752-8062
• DOI: 10.1111/cts.13290

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection among all infants worldwide and remains a significant cause of morbidity and mortality. To address this unmet medical need, MK‐1654, a half‐life extended RSV neutralizing monoclonal antibody, is in clinical development for the prevention of RSV disease in infants. This was a phase I, randomized, placebo‐controlled, single‐site, double‐blind trial of MK‐1654 in 44 healthy Japanese adults. The safety, tolerability, pharmacokinetics, antidrug antibodies (ADAs), and serum neutralizing antibody (SNA) titers against RSV were evaluated for 1 year after a single intramuscular (i.m.) or intravenous (i.v.) dose of MK‐1654 or placebo in five groups (100 mg i.m., 300 mg i.m., 300 mg i.v., 1000 mg i.v., or placebo). MK‐1654 was generally well‐tolerated in Japanese adults. There were no serious drug‐related adverse events (AEs) reported in any MK‐1654 recipient and no discontinuations due to any AEs in the study. The half‐life of MK‐1654 ranged from 76 to 91 days across dosing groups. Estimated bioavailability was 86% for 100 mg i.m. and 77% for 300 mg i.m. One participant out of 33 (3.0%) developed detectable ADA with no apparent associated AEs. The RSV SNA titers increased in a dose‐dependent manner among participants who received MK‐1654. These data support the development of MK‐1654 for use in Japanese infants.